Toxicity endpoint selections for a simazine risk assessment

Area of Science:

• Environmental toxicology
• Pesticide risk assessment
• Endocrine disruption

Background:

• Simazine is used extensively in California, with high exposure levels.
• Simazine is linked to neuroendocrine disruption and mammary cancer in animal studies.
• Prioritized risk assessment due to non-dietary exposure concerns for various populations, including children.

Purpose of the Study:

• To assess the non-dietary risks of simazine exposure in California.
• To determine acceptable exposure levels for occupational/non-occupational users, residents, and bystanders.
• To evaluate risks, especially for children, considering potential pica behavior.

Main Methods:

• Utilized No Observed Effect Levels (NOELs) from animal studies and human exposure data.
• Reviewed oral exposure effects of simazine and its major metabolites (desisopropyl-s-atrazine, diaminochlorotriazine).
• Applied uncertainty factors and calculated margins of exposure for risk characterization.

Main Results:

• Identified critical NOELs from developmental, reproductive, and chronic studies for various exposure durations.
• Calculated a benchmark dose for mammary tumorigenesis in rats.
• Found margins of exposure below acceptable levels for most scenarios, particularly for children.

Conclusions:

• Simazine exposure is associated with fetal developmental delays, endocrine disruption, and mammary tumors.
• Risk assessment indicates inadequate safety margins for key populations, especially children.
• The findings raise concerns regarding potential long-term human health effects from simazine exposure.